A pharmacoeconomic appraisal of therapies for hepatitis B and C.
In the recent years, advances in the treatment of chronic hepatitis B and C have shown that newer, more expensive therapy may result in higher sustained viral response rates. In light of this, the pertinent question for healthcare decision-makers centres around whether this increase in efficacy 'justifies' the additional cost. Pharmacoeconomics is dedicated to helping answer these types of questions. In this article, we will discuss the clinical aspects of hepatitis B and C, recent advances in treatment and studies of the cost-effectiveness of these treatments.
Younossi
Z M
ZM
I.H. Page Center for Health Outcomes Research & Center for Liver Diseases, Inova Fairfax Hospital, 3300 Gallows Road, Falls Church, VA 22042-3300, USA.
Temple
M E
ME
Shermock
K M
KM
D000998:Antiviral Agents / Q000191:economics* / Q000627:therapeutic use; D003365:Costs and Cost Analysis; D004359:Drug Therapy, Combination; D016174:Hepacivirus / Q000187:drug effects; D006509:Hepatitis B / Q000188:drug therapy / Q000191:economics* / Q000821:virology; D006515:Hepatitis B virus / Q000187:drug effects; D006526:Hepatitis C / Q000188:drug therapy / Q000191:economics* / Q000821:virology; D006801:Humans; D016898:Interferon-alpha / Q000191:economics / Q000627:therapeutic use; D012254:Ribavirin / Q000191:economics / Q000627:therapeutic use
D000998:Antiviral Agents; D016898:Interferon-alpha; D012254:Ribavirin